Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Status epilepticus as a complication after COVID-19 mRNA-1273 vaccine: A case report

R. Šín, D. Štruncová

. 2021 ; 9 (24) : 7218-7223. [pub] 2021Aug26

Jazyk angličtina Země Spojené státy americké

Typ dokumentu kazuistiky

Perzistentní odkaz   https://www.medvik.cz/link/bmc21024082

BACKGROUND: We present a rare case of status epilepticus in a 56-year-old man which arose as a complication after vaccination with the coronavirus disease 2019 (COVID-19) mRNA-1273 vaccine. The patient's history included well-compensated secondary epilepsy. The root cause of the situation was a fever which had developed as a side effect of the vaccination. CASE SUMMARY: A 56-year-old man received the first dose of mRNA-1273 vaccine against the severe acute respiratory syndrome-coronavirus-2. The vaccine was administered intramuscularly (100 mg, 0.5 mL). The next morning the man was found to be suffering from fever and headaches while at the same time experiencing general weakness. He lost consciousness suddenly and experienced generalized clonic seizures which turned into status epilepticus. When the Emergency Medical Service arrived the patient was unconscious with spontaneous breathing and generalized clonic seizures. It was necessary to administer diazepam repeatedly. It was also necessary to administer high doses of levetiracetam and temporary propofol. The status epilepticus was brought under control approximately 90 min after the patient's transport to the Emergency Department. A follow-up electroencephalogram no longer revealed abnormal indications of epileptic fit. The patient was temporarily hospitalized in the Intensive Care Unit and after seven days care was discharged without any further apparent effects. CONCLUSION: There is currently no specific treatment against COVID-19. Therefore, the benefits of COVID-19 vaccine protection outweigh the risks.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21024082
003      
CZ-PrNML
005      
20211013134049.0
007      
ta
008      
211006s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.12998/wjcc.v9.i24.7218 $2 doi
035    __
$a (PubMed)34540981
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Šín, Robin $u Department of Infectious Diseases and Travel Medicine, Faculty of Medicine in Pilsen, Charles University, University Hospital Pilsen, Pilsen 30599, Czech Republic
245    10
$a Status epilepticus as a complication after COVID-19 mRNA-1273 vaccine: A case report / $c R. Šín, D. Štruncová
520    9_
$a BACKGROUND: We present a rare case of status epilepticus in a 56-year-old man which arose as a complication after vaccination with the coronavirus disease 2019 (COVID-19) mRNA-1273 vaccine. The patient's history included well-compensated secondary epilepsy. The root cause of the situation was a fever which had developed as a side effect of the vaccination. CASE SUMMARY: A 56-year-old man received the first dose of mRNA-1273 vaccine against the severe acute respiratory syndrome-coronavirus-2. The vaccine was administered intramuscularly (100 mg, 0.5 mL). The next morning the man was found to be suffering from fever and headaches while at the same time experiencing general weakness. He lost consciousness suddenly and experienced generalized clonic seizures which turned into status epilepticus. When the Emergency Medical Service arrived the patient was unconscious with spontaneous breathing and generalized clonic seizures. It was necessary to administer diazepam repeatedly. It was also necessary to administer high doses of levetiracetam and temporary propofol. The status epilepticus was brought under control approximately 90 min after the patient's transport to the Emergency Department. A follow-up electroencephalogram no longer revealed abnormal indications of epileptic fit. The patient was temporarily hospitalized in the Intensive Care Unit and after seven days care was discharged without any further apparent effects. CONCLUSION: There is currently no specific treatment against COVID-19. Therefore, the benefits of COVID-19 vaccine protection outweigh the risks.
655    _2
$a kazuistiky $7 D002363
700    1_
$a Štruncová, Denisa $u Department of Anaesthesiology and Intensive Care Medicine, University Hospital Pilsen, Pilsen 30460, Czech Republic
773    0_
$w MED00186392 $t World journal of clinical cases $x 2307-8960 $g Roč. 9, č. 24 (2021), s. 7218-7223
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34540981 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20211006 $b ABA008
991    __
$a 20211013134046 $b ABA008
999    __
$a ind $b bmc $g 1708185 $s 1144579
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 9 $c 24 $d 7218-7223 $e 2021Aug26 $i 2307-8960 $m World journal of clinical cases $n World J Clin Cases $x MED00186392
LZP    __
$a Pubmed-20211006

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...